Neurocrine Biosciences, Inc. (NBIX) announced the presentation of new data from the Phase 2 SAVITRI study, which showed statistically significant and clinically meaningful improvement in depression severity at Day 28 and Day 56 with once-daily oral administration of 1 mg osavampator. The company said the study met its primary efficacy endpoint, showing a significant reduction in depression severity from baseline to Day 28 compared to placebo. Osavampator was generally well tolerated at both doses, with no serious adverse events or adverse events of special interest reported.
Sanjay Keswani, Chief Medical Officer, Neurocrine, said: "We are encouraged by these results that show osavampator may help address this unmet need by modulating AMPA receptor activity."
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.